The mRNA technology platform has achieved another milestone, with global innovation efforts accelerating.

Recently, the IND application for a Class 1 new drug— "Respiratory Syncytial Virus mRNA Vaccine" —jointly submitted by Ab&B Bio-Tech Co. Ltd. JS (Ab&B Bio) and its subsidiary Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) was approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration.

Ab&B Bio-Tech Co., Ltd. collaborates with Walvax Biotechnology Co., Ltd. to seamlessly connect the third-generation subunit influenza vaccine and embark on a new journey of going global

On March 13, 2026, Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) and its parent company Ab&B Bio Tech Co., Ltd. (Ab&B Bio) officially signed a strategic cooperation agreement for the overseas market of influenza virus subunit vaccines with Watson Biotech Hong Kong Limited (hereinafter referred to as "Watson Hong Kong") in Taizhou. Both parties announced that they will jointly promote Ab&B Bio's independently developed influenza virus subunit vaccine to set sail overseas. This is not only a milestone moment for Chinese vaccine companies to cooperate and build a healthy industry ecosystem, but also signifies that China will bring safer and more effective solutions to the global influenza prevention and control field.

Monkeypox mRNA Vaccine Secures FDA Clinical Approval, Trivalent Influenza Virus Subunit Vaccine Wins First Bid in Shanxi

Recently, Yither Biotech (Shanghai) Co., Ltd. (Yither Bio) and its parent company Ab&B Bio Tech Co., Ltd. (Ab&B Bio) have achieved multiple breakthroughs in innovative vaccine research and commercialization. The independently developed monkeypox mRNA vaccine has obtained clinical trial approval from the US FDA and is the first and only domestically approved trivalent influenza virus subunit vaccine with full dose for the entire population. In response to the WHO's official release of recommended components for seasonal influenza vaccines in the Northern Hemisphere for 2026-2027, it has successfully won the bid in Shanxi Province. This marks a new milestone for Zhonghui Biotechnology in its internationalization journey, policy response speed, and market access capabilities.